Biomarkers of subclinical atherosclerosis in patients with psoriasis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Hannah Kaiser
  • Xing Wang
  • Amanda Kvist-Hansen
  • Martin Krakauer
  • Peter Michael Gørtz
  • Benjamin D. McCauley
  • Skov, Lone
  • Christine Becker
  • Hansen, Peter Riis

Psoriasis is linked with increased risk of cardiovascular disease (CVD) that is underestimated by traditional risk stratification. We conducted a large-scale plasma proteomic analysis by use of a proximity extension assay in 85 patients with a history of moderate-to-severe psoriasis with or without established atherosclerotic CVD. Differentially expressed proteins associated with CVD were correlated with subclinical atherosclerotic markers including vascular inflammation determined by 18F-fluorodeoxyglucose positron emission tomography/computed tomography, carotid intima-media thickness (CIMT), carotid artery plaques, and coronary artery calcium score (CCS) in the patients without CVD and statin treatment. We also examined the association between the neutrophil-to-lymphocyte ratio (NLR) and subclinical atherosclerosis. In unadjusted analyses, growth differentiation factor-15 (GDF-15) levels and NLR were increased, while tumor necrosis factor (TNF)-related activation-inducing ligand (TRANCE) and TNF-related apoptosis-induced ligand (TRAIL) levels were decreased in patients with established CVD compared to those without CVD. Among patients with psoriasis without CVD and statin treatment, GDF-15 levels were negatively associated with vascular inflammation in the ascending aorta and entire aorta, and positively associated with CIMT and CCS. NLR was positively associated with vascular inflammation in the carotid arteries. Our data suggest that circulating GDF-15 levels and NLR might serve as biomarkers of subclinical atherosclerosis in patients with psoriasis.

OriginalsprogEngelsk
Artikelnummer21438
TidsskriftScientific Reports
Vol/bind11
Udgave nummer1
Antal sider11
ISSN2045-2322
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
LEO Foundation supported this study (Grant No. LF16115).

Funding Information:
P.R.H. is recipient of a Borregaard Clinical Scientist Fellowship from the NOVO Nordisk Foundation and chairs a clinical academic group supported by the Greater Region of Copenhagen Health Science Partners. C.B. is a consultant for Onegevity Health. L.S. has been a paid speaker for Eli Lilly, AbbVie and LEO Pharma, and has been a consultant or served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Admirall and Sanofi. She has served as an investigator for AbbVie, Janssen Cilag, Boehringer Ingelheim, AstraZenica, Eli Lilly, Novartis, Regeneron and LEO Pharma, and has received research and educational grants from Pfizer, AbbVie, Novartis, Sanofi, Janssen Cilag and Leo Pharma. H.K., X.W., A.K-H., M.K., P.M.G and B.M have nothing to declare.

Publisher Copyright:
© 2021, The Author(s).

ID: 284703298